Immunomodulatory drugs: New options for the treatment of myelodysplastic syndromes

Roberto Castelli, Ramona Cassin, Antonino Cannavò, Massimo Cugno

Research output: Contribution to journalArticle

Abstract

Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ineffective hematopoiesis with progressive cytopenia and a risk of evolving into currently incurable acute myeloid leukemia. Until recently, the only treatment was bone marrow transplantation, but, over the past few years, a new therapeutic approach based on immunomodulatory drugs (IMiD) has been developed. IMiDs belong to a therapeutic class whose progenitor is thalidomide, a synthetic derivative of glutamate that was initially used because of its sedative and antiemetic properties but was then withdrawn because of its teratogenic effects. IMiDs represent a major advance in the treatment of multiple myeloma at different disease stages, 5q minus syndrome, acute myeloid leukemia with the 5q deletion, mantle cell lymphoma, relapsing or unresponsive high-grade lymphoma, and relapsing indolent lymphoma. Methods: Medical databases and conference proceedings were searched to identify articles and clinical trials that have investigated or are investigating the use of IMiDs on MDS. Results and Discussion: An important part of their in vivo efficacy is attributed to their immunomodulatory properties because they potentiate the immune response by restoring dendritic cell function and inhibiting T-cell regulatory activity, which leads to the activation of T lymphocytes and natural killer T cells by increasing the production of interleukin-2 and interferon gamma. IMiDs are characterized by antitumoral and antiangiogenic activities, and they also induce the apoptosis of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their action on the immune mechanisms that appear to play an important role in the pathophysiology of this syndrome. Conclusions: This article examines the pharmacology and molecular action of IMiDs and the evidence of their efficacy in treating patients with MDS in different risk classes.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Myelodysplastic Syndromes
Thalidomide
Pharmaceutical Preparations
Acute Myeloid Leukemia
Therapeutics
Mantle-Cell Lymphoma
Natural Killer T-Cells
Antiemetics
Hematopoiesis
Regulatory T-Lymphocytes
Hypnotics and Sedatives
Multiple Myeloma
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Dendritic Cells
Interferon-gamma
Interleukin-2
Glutamic Acid
Lymphoma
Clinical Trials

Keywords

  • 5q- deletions
  • Hematologic malignancies
  • Immunomodulatory drugs
  • Lenalidomide
  • Myelodysplastic syndromes
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Immunomodulatory drugs : New options for the treatment of myelodysplastic syndromes. / Castelli, Roberto; Cassin, Ramona; Cannavò, Antonino; Cugno, Massimo.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 1, 02.2013, p. 1-7.

Research output: Contribution to journalArticle

Castelli, Roberto ; Cassin, Ramona ; Cannavò, Antonino ; Cugno, Massimo. / Immunomodulatory drugs : New options for the treatment of myelodysplastic syndromes. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 1. pp. 1-7.
@article{5e2e018bc97c4353918cc29d9f9d7be5,
title = "Immunomodulatory drugs: New options for the treatment of myelodysplastic syndromes",
abstract = "Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ineffective hematopoiesis with progressive cytopenia and a risk of evolving into currently incurable acute myeloid leukemia. Until recently, the only treatment was bone marrow transplantation, but, over the past few years, a new therapeutic approach based on immunomodulatory drugs (IMiD) has been developed. IMiDs belong to a therapeutic class whose progenitor is thalidomide, a synthetic derivative of glutamate that was initially used because of its sedative and antiemetic properties but was then withdrawn because of its teratogenic effects. IMiDs represent a major advance in the treatment of multiple myeloma at different disease stages, 5q minus syndrome, acute myeloid leukemia with the 5q deletion, mantle cell lymphoma, relapsing or unresponsive high-grade lymphoma, and relapsing indolent lymphoma. Methods: Medical databases and conference proceedings were searched to identify articles and clinical trials that have investigated or are investigating the use of IMiDs on MDS. Results and Discussion: An important part of their in vivo efficacy is attributed to their immunomodulatory properties because they potentiate the immune response by restoring dendritic cell function and inhibiting T-cell regulatory activity, which leads to the activation of T lymphocytes and natural killer T cells by increasing the production of interleukin-2 and interferon gamma. IMiDs are characterized by antitumoral and antiangiogenic activities, and they also induce the apoptosis of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their action on the immune mechanisms that appear to play an important role in the pathophysiology of this syndrome. Conclusions: This article examines the pharmacology and molecular action of IMiDs and the evidence of their efficacy in treating patients with MDS in different risk classes.",
keywords = "5q- deletions, Hematologic malignancies, Immunomodulatory drugs, Lenalidomide, Myelodysplastic syndromes, Thalidomide",
author = "Roberto Castelli and Ramona Cassin and Antonino Cannav{\`o} and Massimo Cugno",
year = "2013",
month = "2",
doi = "10.1016/j.clml.2012.09.016",
language = "English",
volume = "13",
pages = "1--7",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "1",

}

TY - JOUR

T1 - Immunomodulatory drugs

T2 - New options for the treatment of myelodysplastic syndromes

AU - Castelli, Roberto

AU - Cassin, Ramona

AU - Cannavò, Antonino

AU - Cugno, Massimo

PY - 2013/2

Y1 - 2013/2

N2 - Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ineffective hematopoiesis with progressive cytopenia and a risk of evolving into currently incurable acute myeloid leukemia. Until recently, the only treatment was bone marrow transplantation, but, over the past few years, a new therapeutic approach based on immunomodulatory drugs (IMiD) has been developed. IMiDs belong to a therapeutic class whose progenitor is thalidomide, a synthetic derivative of glutamate that was initially used because of its sedative and antiemetic properties but was then withdrawn because of its teratogenic effects. IMiDs represent a major advance in the treatment of multiple myeloma at different disease stages, 5q minus syndrome, acute myeloid leukemia with the 5q deletion, mantle cell lymphoma, relapsing or unresponsive high-grade lymphoma, and relapsing indolent lymphoma. Methods: Medical databases and conference proceedings were searched to identify articles and clinical trials that have investigated or are investigating the use of IMiDs on MDS. Results and Discussion: An important part of their in vivo efficacy is attributed to their immunomodulatory properties because they potentiate the immune response by restoring dendritic cell function and inhibiting T-cell regulatory activity, which leads to the activation of T lymphocytes and natural killer T cells by increasing the production of interleukin-2 and interferon gamma. IMiDs are characterized by antitumoral and antiangiogenic activities, and they also induce the apoptosis of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their action on the immune mechanisms that appear to play an important role in the pathophysiology of this syndrome. Conclusions: This article examines the pharmacology and molecular action of IMiDs and the evidence of their efficacy in treating patients with MDS in different risk classes.

AB - Background: Myelodysplastic syndromes (MDS) are common adult hematologic disorders characterized by ineffective hematopoiesis with progressive cytopenia and a risk of evolving into currently incurable acute myeloid leukemia. Until recently, the only treatment was bone marrow transplantation, but, over the past few years, a new therapeutic approach based on immunomodulatory drugs (IMiD) has been developed. IMiDs belong to a therapeutic class whose progenitor is thalidomide, a synthetic derivative of glutamate that was initially used because of its sedative and antiemetic properties but was then withdrawn because of its teratogenic effects. IMiDs represent a major advance in the treatment of multiple myeloma at different disease stages, 5q minus syndrome, acute myeloid leukemia with the 5q deletion, mantle cell lymphoma, relapsing or unresponsive high-grade lymphoma, and relapsing indolent lymphoma. Methods: Medical databases and conference proceedings were searched to identify articles and clinical trials that have investigated or are investigating the use of IMiDs on MDS. Results and Discussion: An important part of their in vivo efficacy is attributed to their immunomodulatory properties because they potentiate the immune response by restoring dendritic cell function and inhibiting T-cell regulatory activity, which leads to the activation of T lymphocytes and natural killer T cells by increasing the production of interleukin-2 and interferon gamma. IMiDs are characterized by antitumoral and antiangiogenic activities, and they also induce the apoptosis of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their action on the immune mechanisms that appear to play an important role in the pathophysiology of this syndrome. Conclusions: This article examines the pharmacology and molecular action of IMiDs and the evidence of their efficacy in treating patients with MDS in different risk classes.

KW - 5q- deletions

KW - Hematologic malignancies

KW - Immunomodulatory drugs

KW - Lenalidomide

KW - Myelodysplastic syndromes

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84873299695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873299695&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.09.016

DO - 10.1016/j.clml.2012.09.016

M3 - Article

C2 - 23153925

AN - SCOPUS:84873299695

VL - 13

SP - 1

EP - 7

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 1

ER -